In vivo differentiation of adipose-derived stem cells in an injectable poloxamer-octapeptide hybrid hydrogel.
Huang J., Wang S., Wei C., Xu Y., Wang Y., Jin J.
Animal Study, published in Tissue Cell (2011) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Tissue Cell (2011)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 21899869
- DOI
- 10.1016/j.tice.2011.07.002
- Citations
- 14
Abstract (original English)
A hybrid hydrogel (PP) composed of Polomaxer-407 (PO) and octapeptide with amino acid sequence of KFEFKFEF (PE) was prepared to make a scaffold material incorporating PO's high and tunable mechanical strength and integrity with PE's superior bioactivity. Human adipose-derived mesenchymal stem cells (hASCs) were encapsulated into PE, PO and PP hydrogels respectively and injected subcutaneously at the dorsal neck area of nude mice. Adipose-like tissue regeneration was only observed in the mice injected with cell-encapsulated PP hydrogel. No adipose regeneration was found in the mice injected with PO or PE. Immunohistochemistry analysis with mouse anti-human nuclei monoclonal antibody demonstrated that the cells in the regenerated adipose-like tissue was originated from the injected hASCs. The growth of blood capillaries indicated that the regenerated adipose-like tissue was living tissue. In addition, human-originated cells were also found in nude mice skin. These cells were positive with mouse anti-human cells keratin antibody, suggesting that the injected hASCs migrated to the skin and differentiated into epithelial cells in vivo.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.